Pharmacokinetics and safety of fosfomycin and flomoxef administered as part of neonatal sepsis treatment (NeoSep1 Part 1)
Pharmakokinetik und Sicherheit von Fosfomycin und Flomoxef im Rahmen der neonatalen Sepsisbehandlung (NeoSep1 Teil 1)
Antimicrobial Agents and Chemotherapy · 04.02.2026 · 70 (2)
DOI: 10.1128/aac.01126-25 ↗Auf einen Blick
Bei 62 Neugeborenen mit Verdacht auf Sepsis wurden Pharmakokinetik und Sicherheit von Fosfomycin und Flomoxef untersucht. Die Expositionen stützten die vorgeschlagenen Dosierungen; behandlungsbezogene Nebenwirkungen waren meist leicht.
Fragestellung
Wirksamkeit, Pharmakokinetik und Sicherheit der vorgeschlagenen neonatalen Dosierungen von Fosfomycin und Flomoxef vor einer größeren Studie zu bestätigen.
Methode
PK- und Sicherheitsstudie bei Neugeborenen mit Verdacht auf Sepsis; sequenzielle Zuteilung zu 3 Antibiotikakohorten; 28 Tage Nachbeobachtung; Populations-PK-Modellierung und Simulationen.
Ergebnisse
62 Neugeborene erhielten mindestens 1 Dosis. Fosfomycin: 2-Kompartiment-Modell; Flomoxef: 1-Kompartiment-Modell. PTA 100 % bis MIC 8 mg/L bzw. 0,5 mg/L. 13 (21 %) entwickelten 19 AEs; 7 (11,6 %) starben.
Schlussfolgerung der Autor:innen
Fosfomycin und Flomoxef waren in dieser überwiegend frühgeborenen Population sicher, und die Arzneiexpositionen entsprachen veröffentlichten Daten; die vorgeschlagenen Dosen wurden unterstützt.
Kernaussagen
- 62 Neugeborene mit Verdacht auf Sepsis erhielten Studienantibiotika
- PTA 100 % bis MIC 8 mg/L bzw. 0,5 mg/L
- 13 (21 %) mit 19 antibiotikabezogenen AEs; keine Therapieänderung nötig
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 04.02.2026. Verfasst von Adrie Bekker und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa. Hauptthemen laut MEDLINE: Fosfomycin, Anti-Bacterial Agents, Neonatal Sepsis, Cephalosporins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK National Institute of Health Research.
Themen: Sepsis
Abstract (Originalsprache)
Neonatal doses for the off-patent antibiotics fosfomycin and flomoxef, which offer coverage against many extended-spectrum beta-lactamase (ESBL)-producing organisms, are based on limited data. We performed a pharmacokinetic (PK) and safety study of fosfomycin and flomoxef to confirm proposed neonatal dosing before further investigation in a trial (NeoSep1, ISRCTN48721236 ). Neonates with suspected sepsis, weighing more than 1,000 g, were sequentially enrolled into three antibiotic treatment cohorts: fosfomycin and amikacin (Cohort 1), flomoxef and amikacin (Cohort 2), and flomoxef and fosfomycin (Cohort 3), and followed for 28 days. Plasma samples were taken for PK assessment, with population PK modeling and simulations performed. Sixty-two neonates (48/62 [77%] preterm; 48/62 [77%] ≤7 days postnatal age [PNA]) received at least one dose of study antibiotics. Fosfomycin and flomoxef plasma concentrations were best described by a two-compartment and a one-compartment model, respectively, with postmenstrual age and PNA significantly influencing clearance. The probability of target attainment for fosfomycin was 100% for minimum inhibitory concentrations (MICs) of up to 8 mg/L, and for flomoxef, it was 100% for MICs of up to 0.5 mg/L. Adverse events (AEs) were common in this critically ill cohort. Thirteen (21%) neonates developed 19 trial antibiotic-related AEs (17 with grade ≤2, and 2 of grade 3), none of which required modification or discontinuation of allocated treatment. Seven neonates (11.6%) died. In this predominately preterm population, fosfomycin and flomoxef were safe, with drug exposures similar to published studies supporting the proposed doses for the larger, randomized NeoSep1 trial. This study is registered with ISRCTN48721236 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.
- Faculty of Pharmacy, University of Payap, Chiang Mai, Thailand.
- Centre for Neonatal and Paediatric Infection, Institute for Infection & Immunity, City St George's, London, United Kingdom.
- MRC Clinical Trials Unit at UCL, London, United Kingdom.
- Global Antibiotic Research and Development Partnership (GARDP), Geneva, Switzerland.
- Division of Medical Microbiology, Department of Pathology, Stellenbosch University and National Health Laboratory Service, Tygerberg Hospital, Cape Town, South Africa.
ORCID-Profile: Adrie Bekker, Silke Gastine, Joseph F Standing, Tim R Cressey
Förderung
- UK National Institute of Health Research
Zitieren
APA
Bekker, A., Panjasawatwong, N., Hill, L. F., Stohr, W., Walker, A. S., Ellis, S., Dramowski, A., Whitelaw, A., Obiero, C., Berkley, J. A., Makazi, A., Velaphi, S., Thomas, R., Magagula, P., Abrahams, I., Nakwa, F. L., Barday, M. M., Van Kwawegen, A., Pillay, K., …, & NeoSep Study Team (2026). Pharmacokinetics and safety of fosfomycin and flomoxef administered as part of neonatal sepsis treatment (NeoSep1 Part 1). Antimicrobial Agents and Chemotherapy, 70(2). https://doi.org/10.1128/aac.01126-25
Vancouver
Bekker A, Panjasawatwong N, Hill LF, Stohr W, Walker AS, Ellis S, et al. Pharmacokinetics and safety of fosfomycin and flomoxef administered as part of neonatal sepsis treatment (NeoSep1 Part 1). Antimicrobial Agents and Chemotherapy. 2026;70(2). doi:10.1128/aac.01126-25
BibTeX
@article{Bekker2026,
author = {Bekker, Adrie and Panjasawatwong, Navarat and Hill, Louise F and Stohr, Wolfgang and Walker, A Sarah and Ellis, Sally and Dramowski, Angela and Whitelaw, Andrew and Obiero, Christina and Berkley, James A and Makazi, Alexander and Velaphi, Sithembiso and Thomas, Reenu and Magagula, Petronella and Abrahams, Ilhaam and Nakwa, Firdose L and Barday, Mohammed M and Van Kwawegen, Alison and Pillay, Kamla and Gastine, Silke and Standing, Joseph F and Skoutari, Peter and Schiavone, Francesca and Sharland, Mike and O'Brien, Seamus and Bielicki, Julia A and Cressey, Tim R and NeoSep Study Team, NeoSep Study Team},
title = {Pharmacokinetics and safety of fosfomycin and flomoxef administered as part of neonatal sepsis treatment (NeoSep1 Part 1)},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {2},
doi = {10.1128/aac.01126-25}
}
EUVIMED